Charley, I really wish I had more money so i could buy more of this stock. Don't fret. I am a pharmaceutical scientist and people in the industry know that this drug development strategy is a winner. Merck and Novartis balked because they are both still dragging through cost-cutting campaigns, laying off thousands of workers, and consolidating what they have, including narrowing the focus of their R&D programs. They just don't have the expertise, time, and money to take the risk of redirecting their existing R&D efforts into this development strategy yet. Remember, RNAi is not a product, or even a technology really. It is a drug development strategy with broad applications. God i wish I had more money to buy more shares.